Your search for esrd returned 27 results

Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.

MK-2060 is an investigational monoclonal antibody designed to inhibit the activation of Factor XI and its ability to activate downstream proteins.

FDA-approved antiviral therapies for the treatment and prophylaxis of influenza.

Elacestrant showed a statistically significant and clinically meaningful progression-free survival improvement compared with standard of care.

Camizestrant improved progression-free survival vs fulvestrant in postmenopausal patients with ER+, HER2- advanced breast cancer.

In patients whose tumors had ESR1 mutations, elacestrant reduced the risk of progression or death by 45%.

Monitoring bESR1mut enabled optimization of the endocrine therapy used with a CDK4/6 inhibitor.

Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.

The duration of prior treatment with a CDK4/6 inhibitor appears to impact progression-free survival with elacestrant in ER+/HER2- metastatic breast cancer.

Hemoglobin levels lower, erythropoietin stimulating agent use higher, even for water lead levels below EPA threshold for regulatory action